A JAMA Network Open study published March 13 found that 90% of Medicaid managed care plans cover at least one alcohol use ...

Alcohol use disorder (AUD) is a major global public health issue, affecting more than 28 million adults in the United States ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

Study finds letting teens drink at home may lead to heavier alcohol use 03:59. Some parents might think that letting their ...

Teens who have parental permission to drink are more likely to develop unhealthy relationships with alcohol as adults, a ...

There is a connection between alcohol and anxiety the day after you drink for many reasons, even if you’ve not been diagnosed ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

March 13 (Reuters) - Altimmune (ALT.O), opens new tab said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol ...